振德医疗(603301) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥903,054,567.59, a decrease of 36.87% compared to the same period last year[5] - Net profit attributable to shareholders was ¥63,155,119.11, down 65.58% year-on-year[5] - The basic earnings per share for the period was ¥0.24, reflecting a decline of 70.37% compared to the previous year[6] - The net profit attributable to shareholders for the year-to-date period was ¥300,521,451.57, a decrease of 33.96% compared to the same period last year[5] - Net profit for the third quarter of 2023 was CNY 308,745,291.11, a decline of 33.3% from CNY 462,971,053.32 in the same quarter of 2022[22] - Total comprehensive income for Q3 2023 was ¥323,240,452.44, down from ¥421,257,460.41 in Q3 2022, representing a decrease of approximately 23.3%[23] - Basic earnings per share for Q3 2023 was ¥1.13, compared to ¥2.02 in Q3 2022, reflecting a decline of about 44.3%[23] Revenue Breakdown - Sales revenue from isolation protective products (masks, protective clothing, etc.) was ¥0.32 billion, a significant drop of 93.39% year-on-year[10] - Excluding isolation protective products, the company's revenue was ¥8.71 billion, a decrease of 7.65% year-on-year[10] - The company achieved a total of ¥5.22 billion in sales from isolation protective products in the first three quarters of 2023, down 69.20% year-on-year[10] - Total operating revenue for the first three quarters of 2023 was CNY 3,209,194,823.07, a decrease of 23.5% compared to CNY 4,197,542,725.56 in the same period of 2022[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,705,279,117.33, a decrease of 2.43% from the end of the previous year[6] - The company's total assets as of the end of the third quarter of 2023 amounted to CNY 7,705,279,117.33, compared to CNY 7,896,933,885.12 at the end of the previous year[18] - Total current assets decreased to ¥3,354,549,722.52 from ¥4,133,980,600.76 year-over-year[16] - The total liabilities of the company were CNY 1,996,011,606.65, a decrease from CNY 2,139,939,039.32 year-over-year[18] - Non-current liabilities decreased to CNY 475,812,759.34 from CNY 621,210,462.53 year-over-year, reflecting a reduction of 23.4%[18] - The company's total equity as of the end of the third quarter of 2023 was CNY 5,709,267,510.68, down from CNY 5,756,994,845.80 at the end of the previous year[18] Cash Flow - The company reported a cash flow from operating activities of ¥262,852,224.14, down 12.89% year-on-year[5] - Cash inflow from operating activities for the first three quarters of 2023 was ¥3,823,930,847.44, down 21.8% from ¥4,888,908,254.18 in the same period of 2022[24] - Net cash flow from operating activities for the first three quarters of 2023 was ¥262,852,224.14, a decrease of 12.9% compared to ¥301,735,384.37 in the previous year[25] - Cash outflow from investing activities for the first three quarters of 2023 totaled ¥1,157,904,356.82, an increase of 31% from ¥884,015,526.28 in the same period of 2022[25] - Net cash flow from investing activities for the first three quarters of 2023 was -¥1,055,233,440.43, worsening from -¥623,768,264.99 in the previous year[25] - Cash inflow from financing activities for the first three quarters of 2023 was ¥585,065,805.00, down 74.6% from ¥2,304,227,074.08 in the same period of 2022[25] - Net cash flow from financing activities for the first three quarters of 2023 was -¥74,313,386.63, compared to ¥623,897,439.24 in the previous year, indicating a significant decline[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,578[13] - Zhejiang Zhend Medical Holdings Co., Ltd. holds 49.82% of shares, with 132,739,480 shares pledged[13] - The top 10 shareholders include Zhejiang Zhend Medical Holdings Co., Ltd. and Xuchang Zhend Landscape Greening Engineering Co., Ltd., with no other significant relationships noted[14] Other Information - The company has not reported any significant new strategies or product developments in the current quarter[15] - The company's financial statements are unaudited for the reporting period[16] - The company has adopted new accounting standards starting in 2023, which may affect the financial statements and related disclosures[26] - The company has a long-term equity investment of ¥72,051,985.97 as of September 30, 2023[16] - Research and development expenses for the first three quarters of 2023 were CNY 110,447,381.62, down 31.3% from CNY 160,613,197.60 in the same period of 2022[21]